Adaptin Bio Q3: Cash Falls to $430K, Going Concern Doubt, Pay Deferred
APTN is trading near its 52-week low of $5.6 (12% above the low).
Summary
Adaptin Bio's Q3 10-Q shows $430,333 of cash, a going concern warning, and rising unpaid officer and director compensation, with the last batch of in-the-money A Warrants having expired September 30.
Key Events · Earnings and Guidance · APTN
-
Going Concern Doubt Reiterated
Management states substantial doubt about the ability to continue as a going concern for the next twelve months, with cash of $430,333 against current liabilities of $2,761,098 and an accumulated deficit of $12,600,550.
-
Compensation Being Deferred
Accrued related-party compensation rose to $621,525 from $54,325 and accrued directors' fees to $105,000 from $26,250, a $567,200 increase in accrued compensation as the company conserves cash.
-
Warrant Exercise Cash Taps Closing
Nine-month warrant exercises brought in $1,589,514 gross on 361,251 A Warrant shares and $39,999 on 12,121 Exchange Warrant shares, but the remaining 1,039,091 unexercised A Warrants expired September 30, 2026.
-
Loss Narrows on R&D Cuts
Nine-month net loss was $3,308,749 versus $3,799,551 a year earlier, as R&D fell 64% to $419,700 while G&A held flat at $2,879,444.
Analysis · APTN · Life Sciences
Adaptin Bio closed September with $430,333 of cash against $2.76 million of current liabilities and a $12.6 million accumulated deficit, and management states substantial doubt exists about continuing as a going concern for the next twelve months. To keep the lights on, the company is not paying its people: accrued related-party compensation jumped to $621,525 from $54,325 and accrued directors' fees to $105,000 from $26,250, while accounts payable sits at $1,688,926. The only real cash inflow is warrant exercises, which brought in $1,470,415 net in the nine months, and the remaining 1,039,091 A Warrants expired on September 30, 2026, closing that tap. With the Phase 1 trial of APTN-101 now enrolling and R&D spending cut 64% to $419,700 for the nine months, another equity raise is the likely path, and it would come at the expense of current holders.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, APTN was trading at $6.27 on OTC in the Life Sciences sector, with a market capitalization of approximately $57.9M. The 52-week trading range was $5.60 to $6.27. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.